ArticleEClinicalMedicine2024
Multivariable models of outcomes with [
Article in EClinicalMedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03511664 (VISION), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Who cites it
19 citing papers in PubMed.
- Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [European urology · 2024Trial
- Outcomes of [European journal of nuclear medicine and molecular imaging · 2026Article
- A phase I dose-escalation/expansion study of fractionated-dose and multiple cycle anti-PSMA-targeted alpha emitter 225Ac-J591 in patients with prostate cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Baseline PSMA PET/CT Biomarkers for Patient Selection in [Pharmaceuticals (Basel, Switzerland) · 2026Review
- Novel risk scoring system for patients with metastatic castration-resistant prostate cancer treated with lutetium-177-PSMA-617.The oncologist · 2026Article
- Radiopharmaceutical Therapy in Oncology: Perspectives from Transatlantic Experts.Oncology and therapy · 2026Review
- Emerging evidence for sequencing and combining PSMA-based therapies in prostate cancer.Nature reviews. Urology · 2026Review
- Prompt PSA changes as a prognostic marker for response to PSMA-radioligand therapy.European journal of nuclear medicine and molecular imaging · 2026Article
- PSMA PET/CT-derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer ReceivingRadiology · 2026Article
- Fully automated volumetric assessment of tumor burden using artificial intelligence onEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Combination therapy strategies in engineeredCell communication and signaling : CCS · 2026Review
- The role of multimodality imaging in selection, response assessment, and follow-up of patients receivingInsights into imaging · 2026Article
- Prognostic value of body composition out of PSMA-PET/CT in prostate cancer patients undergoing PSMA-therapy.European journal of nuclear medicine and molecular imaging · 2025Article
- Genomic alterations and associated outcomes in patients with PSMA-positive metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617.The oncologist · 2025Article
- Review
- Prostate Cancer Radioligand Therapy: PSMA and Beyond, Current Landscape and Future Directions.Current oncology reports · 2025Review
- [Role of prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA-PET/CT) in staging].Urologie (Heidelberg, Germany) · 2025Review
- Large Italian Multicenter Study on Prognostic Value of Baselines Variables in mCRPC Patients Treated withDiagnostics (Basel, Switzerland) · 2025Article
- Visceral metastases, platelet dynamics, and PSA decline: from biomarkers to better outcomes in [Theranostics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Background: [ Methods: Adults with progressive post androgen receptor pathway inhibitor and taxane prostate-specific membrane antigen (PSMA)-positive mCRPC received Findings: Patients were randomised between June 2018 and October 2019. Data from all 551 patients in the Interpretation: These models of outcomes with Funding: Novartis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.